Depomed Inc. boosted its pain portfolio with the purchase of Nautilus Neurosciences Inc.’s migraine drug, Cambia (diclofenac potassium for oral solution) for $48.7 million. Nautilus is eligible for an additional $5 million payment based on achievement of sales milestones. Cambia is the only single agent non-steroidal anti-inflammatory specifically indicated for migraine, with $18 million in sales over the past 3 months.
“We see Cambia as a differentiated asset,” Depomed CEO Jim Schoeneck told BioWorld Today. “We thought that it was attractive and had a good niche in the marketplace.”
Triptans are the most commonly used medications for migraines, either alone or in combination with other drugs. That class includes sumatriptan (Imitrex, Glaxosmithline plc), rizatriptan (Maxalt, Merck & Co. Inc.), zolmitriptan (Zomig, IPR Pharmaceuticals Inc.) and others.